584,332 Shares in Compass Therapeutics, Inc. $CMPX Purchased by Atle Fund Management AB

Atle Fund Management AB bought a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 584,332 shares of the company’s stock, valued at approximately $3,138,000.

Other large investors have also added to or reduced their stakes in the company. Flagship Harbor Advisors LLC purchased a new position in shares of Compass Therapeutics in the fourth quarter worth about $32,000. Russell Investments Group Ltd. increased its stake in shares of Compass Therapeutics by 3,933.7% in the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after buying an additional 7,592 shares during the period. CIBC Bancorp USA Inc. purchased a new position in shares of Compass Therapeutics in the third quarter worth $37,000. Creative Planning purchased a new position in shares of Compass Therapeutics in the second quarter worth $30,000. Finally, Victory Capital Management Inc. increased its stake in shares of Compass Therapeutics by 20.6% in the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock worth $44,000 after buying an additional 2,164 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Trading Down 1.1%

NASDAQ CMPX opened at $1.81 on Wednesday. Compass Therapeutics, Inc. has a 12 month low of $1.61 and a 12 month high of $6.88. The stock has a market cap of $325.96 million, a price-to-earnings ratio of -4.41 and a beta of 0.79. The company’s 50 day moving average is $4.33 and its two-hundred day moving average is $5.05.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Sell-side analysts forecast that Compass Therapeutics, Inc. will post -0.44 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on CMPX. William Blair reissued an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. D. Boral Capital restated a “buy” rating and set a $30.00 price objective on shares of Compass Therapeutics in a research note on Monday, April 27th. Wall Street Zen lowered shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Citizens Jmp restated a “market outperform” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 28th. Finally, Raymond James Financial lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.60.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.